Synta (SNTA)- The Signal Looks Real

Posted on July 10, 2012 at 13:22 PM EDT

So what does the market really think about Synta’s (SNTA) lung cancer data? 2 weeks ago, the stock lost 33% in 1 trading session following interim results from the phase II trial for the company’s lead agent, ganetespib. [More...]

Related Stocks:

Array Biopharma, Inc. Onyx Pharmaceuticals, Inc. Synta Pharmaceuticals, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates